Losartan Potassium Tablet, Film Coated
Product Images NDC 42708-055

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 42708-055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qpharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (42708 055 30)

Label for Losartan Potassium Tablets USP, 50 mg, containing 30 film-coated tablets. The label indicates the product is distributed by QPharma, Inc. and includes storage instructions to keep tightly closed and out of reach of children. It is marked as a sample not for sale and for prescription use only.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with a primary endpoint over time in months between Losartan Potassium and Atenolol. The x-axis represents study months up to 66, and the y-axis shows the percentage of patients, ranging from 0 to 16%. Losartan Potassium shows a consistently lower percentage compared to Atenolol, with an adjusted risk reduction of 13% (p=0.021) indicated on the graph.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph showing the percentage of patients with fatal or non-fatal stroke over a study period of 66 months, comparing Losartan Potassium and Atenolol. The graph indicates adjusted risk reduction of 25% for Losartan Potassium with a p-value of 0.001, showing a lower stroke rate versus Atenolol over time.*

FDA Label Image

Figure 3 (Losartan Fig3)

A forest plot figure comparing Losartan Potassium and Atenolol primary endpoint events within demographic subgroups. It shows event rates (%) and hazard ratios with 95% confidence intervals for overall results and categories by age, gender, race, ischemic heart disease, diabetes, and history of cardiovascular disease. The plot helps visualize which treatment is favored across subgroups for the primary composite endpoint and stroke (fatal/non-fatal).*

FDA Label Image

Figure-4 (Losartan Fig4)

A Kaplan-Meier curve graph showing the percentage of patients with an event over 48 months comparing Losartan Potassium and placebo. The graph includes a solid line for Losartan Potassium and a dashed line for placebo, indicating a 16.1% risk reduction with Losartan Potassium and a p-value of 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of the active ingredient Losartan Potassium, showing its molecular composition including a tetrazole ring, biphenyl group, and chlorinated imidazole moiety with the potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.